Switch theme
Sign up to access all valuation multiples
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
2010
3.6K+
LTM Revenue $836M
LTM EBITDA $159M
$2.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Henlius Biotech has a last 12-month revenue of $836M and a last 12-month EBITDA of $159M.
In the most recent fiscal year, Henlius Biotech achieved revenue of $694M and an EBITDA of $134M.
Henlius Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Henlius Biotech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $413M | $694M | XXX | XXX | XXX |
| Gross Profit | $149M | $305M | XXX | XXX | XXX |
| Gross Margin | 36% | 44% | XXX | XXX | XXX |
| EBITDA | -$39.9M | $134M | XXX | XXX | XXX |
| EBITDA Margin | -10% | 19% | XXX | XXX | XXX |
| Net Profit | -$127M | -$89.4M | XXX | XXX | XXX |
| Net Margin | -31% | -13% | XXX | XXX | XXX |
| Net Debt | $280M | $353M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Henlius Biotech's stock price is HKD 30 (or $4).
Henlius Biotech has current market cap of HKD 16.5B (or $2.1B), and EV of HKD 19.6B (or $2.5B).
See Henlius Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5B | $2.1B | XXX | XXX | XXX | XXX | $0.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Henlius Biotech has market cap of $2.1B and EV of $2.5B.
Henlius Biotech's trades at 3.2x LTM EV/Revenue multiple, and 17.0x LTM EBITDA.
Analysts estimate Henlius Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Henlius Biotech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.5B | XXX | XXX | XXX |
| EV/Revenue | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | 18.8x | XXX | XXX | XXX |
| P/E | 30.2x | XXX | XXX | XXX |
| P/E/Growth | 1.5x | XXX | XXX | XXX |
| EV/FCF | 536.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHenlius Biotech's NTM/LTM revenue growth is -2%
Henlius Biotech's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Henlius Biotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Henlius Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Henlius Biotech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 68% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -435% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 17% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 33% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 59% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Henlius Biotech acquired XXX companies to date.
Last acquisition by Henlius Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Henlius Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Henlius Biotech founded? | Henlius Biotech was founded in 2010. |
| Where is Henlius Biotech headquartered? | Henlius Biotech is headquartered in Hong Kong. |
| How many employees does Henlius Biotech have? | As of today, Henlius Biotech has 3.6K+ employees. |
| Is Henlius Biotech publicy listed? | Yes, Henlius Biotech is a public company listed on HKG. |
| What is the stock symbol of Henlius Biotech? | Henlius Biotech trades under 02696 ticker. |
| When did Henlius Biotech go public? | Henlius Biotech went public in 2019. |
| Who are competitors of Henlius Biotech? | Similar companies to Henlius Biotech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Henlius Biotech? | Henlius Biotech's current market cap is $2.1B |
| What is the current revenue of Henlius Biotech? | Henlius Biotech's last 12-month revenue is $836M. |
| What is the current EBITDA of Henlius Biotech? | Henlius Biotech's last 12-month EBITDA is $159M. |
| What is the current EV/Revenue multiple of Henlius Biotech? | Current revenue multiple of Henlius Biotech is 3.2x. |
| What is the current EV/EBITDA multiple of Henlius Biotech? | Current EBITDA multiple of Henlius Biotech is 17.0x. |
| What is the current revenue growth of Henlius Biotech? | Henlius Biotech revenue growth between 2023 and 2024 was 68%. |
| Is Henlius Biotech profitable? | Yes, Henlius Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
